REGENXBIO Doses First Patient in NAAVIGATE Gene Trial
ROCKVILLE, Md., June 29, 2026 REGENXBIO Inc. has reached a major milestone in the advancement of gene therapy for...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology oncology innovation Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine targeted therapy
ROCKVILLE, Md., June 29, 2026 REGENXBIO Inc. has reached a major milestone in the advancement of gene therapy for...
